Cargando…
Role of the SLC26A9 Chloride Channel as Disease Modifier and Potential Therapeutic Target in Cystic Fibrosis
The solute carrier family 26, member 9 (SLC26A9) is an epithelial chloride channel that is expressed in several organs affected in patients with cystic fibrosis (CF) including the lungs, the pancreas, and the intestine. Emerging evidence suggests SLC26A9 as a modulator of wild-type and mutant CFTR f...
Autores principales: | Balázs, Anita, Mall, Marcus A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174851/ https://www.ncbi.nlm.nih.gov/pubmed/30327603 http://dx.doi.org/10.3389/fphar.2018.01112 |
Ejemplares similares
-
SLC26A9 as a Potential Modifier and Therapeutic Target in Cystic Fibrosis Lung Disease
por: Gorrieri, Giulia, et al.
Publicado: (2022) -
SLC26A9 Gene Is Associated With Lung Function Response to Ivacaftor in Patients With Cystic Fibrosis
por: Corvol, Harriet, et al.
Publicado: (2018) -
Synergy in Cystic Fibrosis Therapies: Targeting SLC26A9
por: Pinto, Madalena C., et al.
Publicado: (2021) -
Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics
por: Strug, Lisa J., et al.
Publicado: (2016) -
Pathogenic Relationships in Cystic Fibrosis and Renal Diseases: CFTR, SLC26A9 and Anoctamins
por: Kunzelmann, Karl, et al.
Publicado: (2023)